8 results
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
The purpose of this study is to improve the prediction of RD episode in patients undergoing opioid therapy in the hospital ward (also known as the General Care Floor) to guide clinicians and nursing staff in selecting the at-risk patients who could…
Primary objective:The primary objective is the difference between the gammaCore®-R and the sham treatment groups in mean reduction in number of episodic migraine days during the last four weeks in the twelve-week randomized period compared with the…
To evaluate safety of 3-months versus standard 12-months of DAPT
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…